Does RUXOLITINIB Cause Myelofibrosis? 1,316 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 1,316 reports of Myelofibrosis have been filed in association with RUXOLITINIB (OPZELURA). This represents 1.9% of all adverse event reports for RUXOLITINIB.
1,316
Reports of Myelofibrosis with RUXOLITINIB
1.9%
of all RUXOLITINIB reports
581
Deaths
446
Hospitalizations
How Dangerous Is Myelofibrosis From RUXOLITINIB?
Of the 1,316 reports, 581 (44.1%) resulted in death, 446 (33.9%) required hospitalization, and 64 (4.9%) were considered life-threatening.
Is Myelofibrosis Listed in the Official Label?
Yes, Myelofibrosis is listed as a known adverse reaction in the official FDA drug label for RUXOLITINIB.
What Other Side Effects Does RUXOLITINIB Cause?
Off label use (12,492)
Death (6,561)
Fatigue (5,663)
Anaemia (3,593)
Haemoglobin decreased (3,297)
Platelet count decreased (3,028)
Diarrhoea (2,531)
Asthenia (2,529)
Dizziness (2,398)
Pneumonia (2,343)
What Other Drugs Cause Myelofibrosis?
ELTROMBOPAG (89)
ROMIPLOSTIM (89)
HYDROXYUREA (88)
IMATINIB (76)
DEFERASIROX (57)
MOMELOTINIB (51)
ASPIRIN (46)
RITUXIMAB (43)
ANAGRELIDE (41)
ELTROMBOPAG OLAMINE (39)
Which RUXOLITINIB Alternatives Have Lower Myelofibrosis Risk?
RUXOLITINIB vs SABRIL
RUXOLITINIB vs SACCHAROMYCES CEREVISIAE
RUXOLITINIB vs SACITUZUMAB GOVITECAN
RUXOLITINIB vs SACITUZUMAB GOVITECAN-HZIY
RUXOLITINIB vs SACROSIDASE